Effects of Intermittent Hypoxia in Upper and Lower Limb Functions in Persons With Incomplete Spinal Cord Injury
Launched by RIPHAH INTERNATIONAL UNIVERSITY · Aug 4, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effects of a treatment called acute intermittent hypoxia (AIH) on people with incomplete spinal cord injuries (iSCI). Incomplete spinal cord injuries mean that some nerve pathways are still functioning, allowing for the potential for recovery. The researchers believe that AIH can help improve movement and balance in the arms and legs, as well as enhance overall quality of life and reduce disability. They want to learn more about how AIH affects these functions and also look at some specific health markers in participants.
To be eligible for the trial, participants must have an incomplete spinal cord injury for at least three months, be aged 18 years or older, and have a specific type of injury classified as ASIA category C or D. They should be able to walk with or without assistance and follow simple commands. However, those with complete spinal cord injuries, certain orthopedic problems, severe skin issues, or significant cognitive challenges are not eligible to participate. If you join the trial, you can expect to undergo evaluations related to your movement abilities and health, and you’ll be contributing to important research that may help others with similar conditions.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Incomplete SCI≥ 3 months(21);
- • 2. Traumatic and non-traumatic, non-progressive lesions, Aged ≥ 18 years ;
- • 3. LesionC4 and below as classified ASIA category C and D;
- • 4. Both gender
- • 5. Ability to ambulate with or without assistive devices; and
- • 6. Ability to follow verbal and visual command.
- Exclusion Criteria:
- • 1. Participants with complete spinal cord injury;
- • 2. Unstable orthopedic injuries and joint contractures
- • 3. Osteoporosis with high risk of fracture;
- • 4. Pressure ulcers and cutaneous lesion(4)
- • 5. Cognitive impairment, severe cardiopulmonary complication such as severe breathing disorder
About Riphah International University
Riphah International University is a leading educational institution based in Pakistan, dedicated to advancing healthcare and medical research through innovative clinical trials. With a commitment to excellence in research and education, Riphah emphasizes ethical standards and scientific integrity in its clinical studies. The university collaborates with various stakeholders, including healthcare professionals and industry partners, to enhance patient outcomes and contribute to the global body of medical knowledge. Through its robust research programs, Riphah International University aims to foster a culture of inquiry and improve healthcare delivery both locally and internationally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Islamabad, , Pakistan
Patients applied
Trial Officials
Ikram Ali, Master
Principal Investigator
Riphah International University Islamabad
Waqar Ahmed Awan, PhD
Study Chair
Riphah International University Islamabad
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials